tiprankstipranks
Cartesian Therapeutics, Inc. (RNAC)
:RNAC
US Market

Cartesian Therapeutics (RNAC) Income Statement

Compare
1,104 Followers

Cartesian Therapeutics Income Statement

Last quarter (Q3 2024), Cartesian Therapeutics's total revenue was $387.00K, a decrease of -94.09% from the same quarter last year. In Q3, Cartesian Therapeutics's net income was $-24.18M. See Cartesian Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 26.00M$ 110.78M$ 85.08M$ 16.60M$ 6.68M
Gross Profit
$ 24.45M$ 108.74M$ 85.08M$ 16.60M$ 6.68M
Operating Expenses
$ 110.87M$ 96.24M$ 89.67M$ 73.42M$ 57.10M
Depreciation and Amortization
$ 843.00K$ 2.04M$ 1.72M$ 1.73M$ 2.03M
EBITDA
$ -235.06M$ 39.84M$ -5.16M$ -65.59M$ -51.80M
Operating Income
$ -86.42M$ 14.54M$ -4.60M$ -56.82M$ -52.45M
Other Income/Expenses
$ -152.29M$ 20.23M$ -5.12M$ -12.05M$ -2.90M
Pretax Income
$ -238.71M$ 34.77M$ -9.72M$ -68.88M$ -55.35M
Net Income
$ -219.71M$ 35.38M$ -25.69M$ -68.88M$ -55.35M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -42.49$ 7.33$ -6.74$ -20.42$ -36.46
Diluted EPS
$ -42.49$ 2.98$ -6.74$ -20.42$ -36.46
Weighted Average Shares Outstanding
5.17M 4.83M 3.81M 3.37M 1.52M
Weighted Average Shares Outstanding (Diluted)
5.17M 4.86M 3.81M 3.37M 1.52M
Currency in USD

Cartesian Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis